Everything below concerns research chemical. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-08-19. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
In Natal, the Battle of the Tugela Heights, which started on 14 February was Buller's fourth attempt to relieve Ladysmith. The losses Buller's troops had sustained convinced Buller to adopt Boer tactics "in the firing line—to advance in small rushes, covered by rifle fire from behind; to use the tactical support of artillery; and above all, to use the ground, making rock and earth work for them as it did for the enemy." Despite reinforcements his progress was painfully slow against stiff opposition. However, on 26 February, after much deliberation, Buller used all his forces in one all-out attack for the first time and succeeded in forcing a crossing of the Tugela to defeat Botha's outnumbered forces north of Colenso. After a siege lasting 118 days, the Relief of Ladysmith was effected, the day after Cronjé surrendered, but at a total cost of 7,000 British casualties. Buller's troops marched into Ladysmith on 28 February. After a succession of defeats, the Boers realised that against such overwhelming numbers of troops, they had little chance and became demoralised. Roberts then advanced into the Orange Free State from the west, putting the Boers to flight at the Battle of Poplar Grove and capturing Bloemfontein, the capital, unopposed on 13 March with the Boer defenders escaping and scattering. Meanwhile, he detached a small force to relieve Baden-Powell. The Relief of Mafeking on 18 May 1900 provoked riotous celebrations in Britain, the origin of the Edwardian slang word "mafficking". On 28 May, the Orange Free State was annexed and renamed the Orange River Colony.
One approach is to determine the optimal host system for each specific target protein product, as different, especially non-native proteins often have deviant behavior in other organisms, and some host systems may produce higher yields, or require more mild conditions than others. Specifically, incorporating different promoters or optimized genetic sequences and using variants or strains of organisms that allow for these post-translational modifications is an approach of interest. For example, variants that have efficient secretion may allow for the production of heterologous expression products to be industrially relevant. Additionally, increasing the availability of cofactors, improving protein folding capacity, improving gene promoters, and designing control systems that change based on differing resource demands. Another approach is incorporating transient periods where heterologous production is lowered to allow for host system recovery. To address errors in translation, it is possible to overexpress tRNA to mitigate any shortages, however, base modifications are still heavily dependent on the host system. Scientists have attempted to design a universal system to attempt to mitigate these concerns, but there is still much to be discovered about the connection between hosts and native producers, and the implications of the increased burden on host systems.
Antihyperglycemic drug used for diabetes mellitus and treatment of hirsutism associated with insulin resistance (e.g. polycystic ovary syndrome). Metformin appears ineffective in the treatment of hirsutism, although the evidence was of low quality. Spironolactone: An antimineralocorticoid with additional antiandrogenic activity at high dosages.
Sources: en.wikipedia.org
== History == Founded in 1993 by Jack Owoc, Bang's parent company manufactured and distributed sports supplements and performance beverages under the brand name VPX. Other products distributed by Vital included Redline, Noo Fuzion, and Meltdown. In 2012, Vital created Bang, marketed as a low sugar carbonated energy drink and with the mission to make high-quality nutritional supplements backed by scientific research. In 2017, it was announced that Bang would offer a caffeine-free variant of the beverage, using beta-alanine in place of caffeine. In 2019, the company opened a manufacturing and distribution facility in Phoenix, Arizona, which operates alongside their facility in Pembroke Pines, Florida. In April 2020, PepsiCo entered into an exclusive distribution agreement with VPX to distribute Bang in the United States. On November 17, 2020, it gave PepsiCo a notice of termination; an emergency arbitrator ruled in December 2020 that Pepsi remained the exclusive distributor of Bang drinks until 2023. VPX resolved their disputes with PepsiCo and transitioned away from their distribution in June 2022. In August 2022, it was reported that Keurig Dr Pepper was in talks to purchase VPX; these talks fell apart shortly after the reports surfaced. On October 10, 2022, Bang's parent company filed for Chapter 11 bankruptcy protection. Three months after Owoc was removed and John DiDonato was named interim CEO of VPX, Monster Beverage reached an agreement for its purchase on June 28, 2023, this was completed one month later.
The decision to release the declaration was taken by the British War Cabinet on 31 October 1917. This followed discussion at four War Cabinet meetings (including the 31 October meeting) over the space of the previous two months. In order to aid the discussions, the War Cabinet Secretariat, led by Maurice Hankey, the Cabinet Secretary and supported by his Assistant Secretaries – primarily Sykes and his fellow Conservative MP and pro-Zionist Leo Amery – solicited outside perspectives to put before the Cabinet. These included the views of government ministers, war allies – notably from President Woodrow Wilson – and in October, formal submissions from six Zionist leaders and four non-Zionist Jews. British officials asked President Wilson for his consent on the matter on two occasions – first on 3 September, when he replied the time was not ripe, and later on 6 October, when he agreed with the release of the declaration.
Sulfur–sulfur bonds are a structural component used to stiffen rubber, similar to the disulfide bridges that rigidify proteins (see biological below). In the most common type of industrial "curing" or hardening and strengthening of natural rubber, elemental sulfur is heated with the rubber to the point that chemical reactions form disulfide bridges between isoprene units of the polymer. This process, patented in 1843, made rubber a major industrial product, especially in automobile tires. Because of the heat and sulfur, the process was named vulcanization, after the Roman god of the forge and volcanism.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.